Post by
Jon9800 on Jun 07, 2022 2:08pm
CEO Hemostemix emphasized on the increasing volatility of $H
Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the stock because of the firm belief.